Invitrogen Corp.

Invitrogen Corp. of Carlsbad, Calif., has entered into an agreement with the National Institutes of Health Chemical Genomics Center in Bethesda, Md., to identify small molecules that modulate key signaling pathways associated with disease pathophysiology. The center will use the company’s CellSensor cell lines and GeneBLAzer β-lactamase reporter gene technology to identify compounds that modulate disease signaling pathways. All of the data will be deposited in PubChem, an NIH database that links chemical structures to biological activities uncovered through screening campaigns. The research community will have access to the database.